Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)Scott Kopetz, Howard S. Höchster, Luis A. Díaz et al.|Journal of Clinical Oncology|2020Cited by 391
ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaperArvind Dasari, Scott Kopetz, Van K. Morris et al.|Nature Reviews Clinical Oncology|2020Cited by 365
Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitorsGregory S. Ducker, Robert S. Warren, Chloé E. Atreya et al.|Oncogene|2013Cited by 92
<scp>PTEN</scp> expression is consistent in colorectal cancer primaries and metastases and associates with patient survivalChloé E. Atreya, Robert S. Warren|Cancer Medicine|2013Cited by 46
Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E–mutated (BRAFm) metastatic colorectal cancer (mCRC)Ryan B. Corcoran, Eric Van Cutsem, Thierry André et al.|Annals of Oncology|2016Cited by 46